The present invention relates to methods for editing the genome of a microbial host cell in successive rounds of transformation. The method allows the introduction of genetic edits into the genome of a microbial host cell in an iterative fashion that does not require the use of functional counterselection following at least one round of transformation. It can be used to rapidly stack genetic edits in the genome of a microbial host cell. Kits for performing the methods are also disclosed.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions in chemically defined media to reduce amounts of certain Aflibercept variants.

The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.

The invention provides compositions and methods for inhibiting the interaction of the SARS-CoV-2 S protein and one or more SARS-CoV-2 S protein interacting protein, and methods of use thereof.

An approach for modifying multiple types of bacteria to produce surface modifications that enhance the immunologic response when used as a vaccine. A series of plasmids (pYF, pYFC, pYFP, pSF, pSPF, and pSCF) may be used to transform bacteria which then produce surface-exposed ligands that bind to complement receptors on antigen presenting cells. When modified bacteria are used as a vaccine, the vaccine recipients produce significantly higher titers of specific antibodies and are better protected against challenges from the disease-causing bacteria.

The present disclosure pertains compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.